Adams Capital Management
All Portfolio Companies Information Technology: Networking Infrastructure Other Featured Exits  

Current Portfolio

Information Technology:

Networking Infrastructure

Other

Featured Exits

Precision Therapeutics

Precision Therapeutics

Initial Investment:

2003

Location:

Pittsburgh, Pennsylvania

ACM Deal Team:

Joel Adams
William Frezza

Overview:

Precision Therapeutics (PTI) is committed to improving outcomes of cancer patients. Known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, PTI develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer. PTI's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician with the goal of optimizing patient outcomes.
www.precisiontherapeutics.com

Recent Precision Therapeutics News

July 22, 2014 Manuscript Demonstrating ChemoFx is a Predictive Marker in Ovarian Cancer Published by the British Journal of Cancer
June 26, 2014 Two Pivotal Manuscripts on ChemoFx Accepted for Publication
 
prevnextBack to Portfolio Page